دورية أكاديمية
أعرض في EDS

Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria.

التفاصيل البيبلوغرافية
العنوان: Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria.
المؤلفون: Shittu KA; Department of Obstetrics and Gynaecology, Lagos State University Teaching Hospital, Ikeja 100271, Lagos State, Nigeria., Rabiu KA; Department of Obstetrics and Gynaecology, Lagos State University College of Medicine, Ikeja 100271, Lagos State, Nigeria., Akinola OI; Department of Obstetrics and Gynaecology, Lagos State University College of Medicine, Ikeja 100271, Lagos State, Nigeria., Ahmed SB; Department of Community Medicine, University College Hospital, Ibadan 200212, Oyo State, Nigeria., Adewunmi AA; Department of Obstetrics and Gynaecology, Lagos State University College of Medicine, Ikeja 100271, Lagos State, Nigeria.
المصدر: Ecancermedicalscience [Ecancermedicalscience] 2023 Jul 05; Vol. 17, pp. 1568. Date of Electronic Publication: 2023 Jul 05 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: ecancer Country of Publication: England NLM ID: 101392236 Publication Model: eCollection Cited Medium: Print ISSN: 1754-6605 (Print) Linking ISSN: 17546605 NLM ISO Abbreviation: Ecancermedicalscience Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: Bristol, UK : ecancer
Original Publication: Bristol, UK : Cancer Intelligence
مستخلص: This prospective cross-sectional study compared the diagnostic accuracy of human epididymal protein 4 (HE4) with cancer antigen 125 (CA 125) and validates the risk of malignancy algorithm (ROMA) in differentiating benign from malignant ovarian tumours. The study population included 112 women with an ultrasound diagnosis of an adnexal mass, out of whom 49 women had a diagnosis of ovarian cancer following optimal debulking surgery, and 63 women had a diagnosis of benign ovarian tumour. All diagnosis was confirmed by histopathological analysis. Serum HE4 and CA 125 were assessed preoperatively according to the manufacturer's instructions. CA 125 and HE4 cut-offs were 35 U/mL and 70 pM/L respectively. Serum CA 125 and HE4 were significantly higher in ovarian cancer patients compared to those with benign ovarian tumours ( p < 0.001 and p < 0.000, respectively). HE4 had higher sensitivity (77.5% versus 69.4%), specificity (96.8% versus 82.5%), positive predictive value (PPV) (95% versus 75.6%) and negative predictive value (84.7% versus 77.6%) than CA 125. When the two markers were combined with each other in the ROMA index, Specificity and PPV reached 100% each. In the receiver operative characteristics analysis, the area under the curve for CA 125 was 0.679 (95% CI 0.566-0.791, p = 0.001), HE4 was 0.845 (95% CI 0.760-0.930, p = 0.000) and ROMA was 0.902 (95% CI 0.851-0.998, p = 0.000) and this was statistically significant ( p < 0.001). Conclusively, HE4 performed better than CA 125 in differentiating benign from malignant ovarian tumours and the combination of the two biomarkers improved the detection of ovarian cancer. In addition, the cut off values corresponding to the highest accuracy for CA 125 and HE4 were 126 U/mL and 42 pM/L respectively in this study. The value for CA 125 is much higher while that of HE4 is much lower than the reference values obtained predominantly from the white population.
Competing Interests: The authors declare that they have no conflicts of interest.
(© the authors; licensee ecancermedicalscience.)
References: Diagn Pathol. 2013 Jan 23;8:11. (PMID: 23343214)
N Engl J Med. 2009 Jul 9;361(2):170-7. (PMID: 19587342)
J Obstet Gynaecol. 2013 Apr;33(3):305-8. (PMID: 23550866)
Clin Chem Lab Med. 2011 Mar;49(3):521-5. (PMID: 21288178)
J Clin Invest. 1981 Nov;68(5):1331-7. (PMID: 7028788)
Int J Gynecol Cancer. 2011 Jul;21(5):852-8. (PMID: 21633297)
BMC Cancer. 2014 Mar 10;14:171. (PMID: 24612526)
Medicine (Baltimore). 2015 Dec;94(52):e2402. (PMID: 26717395)
N Engl J Med. 1983 Oct 13;309(15):883-7. (PMID: 6310399)
Cancers (Basel). 2022 Apr 29;14(9):. (PMID: 35565359)
J Gynecol Oncol. 2011 Dec;22(4):244-52. (PMID: 22247801)
J Clin Pathol. 2013 Apr;66(4):273-81. (PMID: 23426716)
J Ovarian Res. 2013 Jul 01;6(1):44. (PMID: 23816286)
BMC Cancer. 2013 Sep 18;13:423. (PMID: 24044637)
Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81. (PMID: 16343244)
Cancers (Basel). 2020 Dec 11;12(12):. (PMID: 33322519)
Gynecol Oncol. 2009 Jan;112(1):40-6. (PMID: 18851871)
Eur J Obstet Gynecol Reprod Biol. 2013 Mar;167(1):81-5. (PMID: 23228410)
Am J Obstet Gynecol. 2012 Apr;206(4):351.e1-8. (PMID: 22284961)
Gynecol Oncol. 2010 Jun;117(3):440-5. (PMID: 20334903)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Biomed Rep. 2016 Jul;5(1):41-44. (PMID: 27347403)
Br J Cancer. 2011 Mar 1;104(5):863-70. (PMID: 21304524)
فهرسة مساهمة: Keywords: cancer antigen 125; human epididymis protein 4; ovarian cancer; risk of malignancy algorithm
تواريخ الأحداث: Date Created: 20230803 Latest Revision: 20230804
رمز التحديث: 20230804
مُعرف محوري في PubMed: PMC10393307
DOI: 10.3332/ecancer.2023.1568
PMID: 37533954
قاعدة البيانات: MEDLINE
الوصف
تدمد:1754-6605
DOI:10.3332/ecancer.2023.1568